BioPharmSignal logoBioPharmSignal

Biotech News

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Alkermes plc (ALKS)Alkermes plcConference / presentation

DUBLIN --(BUSINESS WIRE)--Jun. 3, 2026-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47 th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET ( 3:00 p.m. BST).

Open original release

Related news

ALKSAlkermes plc2026-05-21 11:00 EST

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

HRMYHarmony Biosciences2026-03-31 12:05 EST

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

ANNXAnnexon, Inc.2026-04-08 20:05 EST

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

ABOSAcumen Pharmaceuticals2026-05-07 20:00 EST

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

ALKSAlkermes plc2026-05-26 11:00 EST

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

NBIXNeurocrine Biosciences2026-05-05 13:00 EST

Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

ANNXAnnexon, Inc.2026-05-06 12:00 EST

Annexon to Present at the Bank of America Securities Health Care Conference 2026

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-06-04 11:00 EST

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

ALKSAlkermes plc2026-05-26 11:00 EST

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

ALKSAlkermes plc2026-05-21 11:00 EST

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

ALKSAlkermes plc2026-05-12 11:00 EST

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Stock data

Close
52.73 USD
Market cap
6.89B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States